株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒト成長ホルモン欠乏症 (GHD) 治療薬の世界市場:現状、パイプライン製品分析、治験動向、市場の潜在力 - 将来予測

Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023

発行 Azoth Analytics 商品コード 630031
出版日 ページ情報 英文 130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
ヒト成長ホルモン欠乏症 (GHD) 治療薬の世界市場:現状、パイプライン製品分析、治験動向、市場の潜在力 - 将来予測 Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023
出版日: 2018年04月23日 ページ情報: 英文 130 Pages
概要

当レポートでは、ヒト成長ホルモン欠乏症 (hGHD) の治療薬の市場について分析し、成長ホルモン欠乏症 (GHD) の概要や主な治療手段、現在治験中の主なパイプライン製品の概略、現在までの治験の進展状況、市場規模の動向見通し、エンドユーザー別・地域別の詳細動向、主な市場促進・抑制要因、主要企業のプロファイルと主力製品などの情報を取りまとめてお届けいたします。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 成長ホルモン欠乏症治療薬:概要

  • 成長ホルモン (GH) とその機能
  • 成長ホルモン欠乏症 (GHD) とその症状
  • 成長ホルモン欠乏症 (GHD) の原因

第4章 成長ホルモン欠乏症 (GHD) の診断方法

第5章 成長ホルモン欠乏症 (GHD) の治療方法

第6章 世界の成長ホルモン薬品の市場

  • 市場規模の実績値 (金額ベース、過去5年間分)
  • 市場規模の予測値 (金額ベース、今後6年間分)

第7章 世界の成長ホルモン欠乏症治療薬の市場

  • 市場規模の実績値 (金額ベース、過去5年間分)
  • 市場規模の予測値 (金額ベース、今後6年間分)

第8章 世界の成長ホルモン欠乏症治療薬の市場:エンドユーザー別

  • エンドユーザー別の市場シェア (%):最新値・予測値
  • 小児用
  • 成人用
    • 市場規模の実績値 (金額ベース、過去5年間分)
    • 市場規模の予測値 (金額ベース、今後6年間分)

第9章 世界の成長ホルモン欠乏症治療薬の市場:地域別

  • 北米市場
  • 欧州市場
  • 他の国々 (RoW) の市場
    • 市場規模の実績値 (金額ベース、過去5年間分)
    • 市場規模の予測値 (金額ベース、今後6年間分)

第10章 世界の成長ホルモン欠乏症治療薬の市場:国別

  • 米国市場
  • 英国市場
  • フランス市場
  • ドイツ市場
  • スペイン市場
  • 日本市場
    • 市場規模の実績値 (金額ベース、過去5年間分)
    • 市場規模の予測値 (金額ベース、今後6年間分)

第11章 ヒト成長ホルモン欠乏症 (hGHD) のパイプライン製品:分析

  • TransCon-hGH
    • 概略
    • 規制のマイルストーン
    • 利点・欠点
    • 製品プロファイルと上市予定日
    • 治験の動向と現状
    • 重要な治験とその結果
    • 世界市場の潜在的な規模
  • Somapacitan
  • Somavaratan
  • Somatrogon/Lagova
  • 競争環境

第12章 企業プロファイル

  • Ascendis Pharma A/S
  • Novo Nordisk A/S
  • Versartis Inc.
  • Opko Health, Inc.
  • Pfizer Inc
図表

List of Figures

  • Figure 1: Global Growth Hormones Drugs Market Size, By value, 2013-2017 (USD Billion)
  • Figure 2: Global Growth Hormones Drugs Market Size, By value, 2018-2023 (USD Billion)
  • Figure 3: Global Growth Hormones Market Share 2017
  • Figure 4: Sales of Growth Hormones, By Value, 2014-2017
  • Figure 5: Global Growth Hormone Market Share, 2017 (%)
  • Figure 6: Global Growth Hormones Deficiency Drugs Market Size, By value, 2013-2017 (USD Billion)
  • Figure 7: Global Growth Hormones Deficiency Drugs Market Size, By value, 2018-2023 (USD Billion)
  • Figure 8: Global Growth Hormone Market 2017
  • Figure 9: Global Growth Hormone Market 2028
  • Figure 10: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2017 (%)
  • Figure 11: Global Growth Hormone Deficiency Drugs Market Share, By End User, 2023 (%)
  • Figure 12: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2013-2017 (USD Billion)
  • Figure 13: Global Growth Hormone Deficiency Drugs Market, By Pediatrics, By Value, 2018-2023 (USD Billion)
  • Figure 14: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2013-2017 (USD Billion)
  • Figure 15: Global Growth Hormone Deficiency Drugs Market, By Adults, By Value, 2018-2023 (USD Billion)
  • Figure 16: North America Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 17: Europe Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 18: ROW Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 19: US Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 20: U.S. Per Capita Health Expenditure, 2012-2016 (USD)
  • Figure 21: U.S Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 22: UK Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 23: France Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 24: France Per Capita Healthcare Expenditure (USD)
  • Figure 25: France Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 26: Germany Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 27: Germany Healthcare Expenditure (USD Billion, 2014-2017
  • Figure 28: Germany Prevalence of Cancer, in cases per 100,000 (2014-2016)
  • Figure 29: Spain Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 30: Japan Growth Hormone Deficiency Drugs Market Size, By value, 2013-2023 (USD Billion)
  • Figure 31: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 32: Change in HT SDS (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 33: Dose Proportional IGF-1 Elevation Observed into the Normal Range
  • Figure 34: Comparable hGH levels for TransCon Growth Hormone and Daily hGH
  • Figure 35: Global TransCon hGH Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 36: Annualized Height Velocity (Mean + SD) of full dataset of 53 patients after 6 months of treatment
  • Figure 37: Global Somapacitan (NN8640) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 38: Height Velocity at 12 months in ITT and PP groups
  • Figure 39: Global Somavaratan (VRS-317) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 40: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
  • Figure 41: Mean annualized HV for subjects completed 24 month of once weekly Somatrogon treatment
  • Figure 42: Global Somatrogon (Lagova) Market Size, By Value, Forecast, 2020-2023 (USD million)
  • Figure 43: Ascendis Pharma Company Net Sales, By Value, in million €
  • Figure 44: Novo Nordisk Company Net Sales, By Value, in million DKK
  • Figure 45: Norditropin® net sales, by value, in million DKK
  • Figure 46: Pfizer Company Revenue, By Value, in million USD
  • Figure 47: Genotropin net sales, by value, in million USD

List of Tables

  • Table A: Upcoming Drugs in the market of Growth Hormone Deficiency and their Clinical Status from 2016 - 2020
目次

The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

The report titled "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 - 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

Scope of the Report

Global Market

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment - TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)

  • Market Potential
  • Clinical Trials
  • Product Description
  • Regulatory Phases
  • 7Ps Analysis

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Regional Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth: North America, Europe, Rest of the World

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Country Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market - Sizing and Growth: US, UK, France, Spain, Germany, Japan

  • Actual Period: 2013-2017
  • Forecast Period: 2018-2023

Other Report Highlights

  • Company Analysis - Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Growth Hormone Deficiency Drugs Product - An Overview

  • 3.1. Growth Hormone (GH) and its Function
  • 3.2. Growth Hormone Deficiency (GHD) and its Symptoms
  • 3.3. Causes of Growth Hormone Deficiency (GHD)

4. Diagnosis of Growth Hormone Deficiency (GHD)

5. Treatment of Growth Hormone Deficiency (GHD)

6. Global Growth Hormone Drugs Market

  • 6.1. Global Growth Hormone Drugs Market Size, By value, 2013-2017
  • 6.2. Global Growth Hormone Drugs Market Size, By value, 2018-2023

7. Global Growth Hormone Deficiency Drugs Market

  • 7.1. Global Growth Hormone Deficiency Drugs Market Size, By value, 2013-2017
  • 7.2. Global Growth Hormone Deficiency Drugs Market Size, By value, 2018-2023

8. Global Growth Hormone Deficiency Drugs Market, By End User

  • 8.1. Global Growth Hormone Deficiency Drugs Market, By End User: Break down (%)
    • 8.1.1. Global Growth Hormone Deficiency Drugs Market, By End User: 2017%
    • 8.1.2. Global Growth Hormone Deficiency Drugs Market, By End User: 2023%
  • 8.2. Global Growth Hormone Deficiency Drugs Market, By End User - By Pediatrics
    • 8.2.1. By Value (2013 - 2017)
    • 8.2.2. By Value (2018 - 2023)
  • 8.3. Global Growth Hormone Deficiency Drugs Market, By End User - By Adult
    • 8.3.1. By Value (2013 - 2017)
    • 8.3.2. By Value (2018 - 2023)

9. Global Growth Hormone Deficiency Drugs Market: Regional Analysis

  • 9.1. North America Growth Hormone Deficiency Drugs Market
    • 9.1.1. By Value (2013 - 2017)
    • 9.1.2. By Value (2018 - 2023)
  • 9.2. Europe Growth Hormone Deficiency Drugs Market
    • 9.2.1. By Value (2013 - 2017)
    • 9.2.2. By Value (2018 - 2023)
  • 9.3. ROW Growth Hormone Deficiency Drugs Market
    • 9.3.1. By Value (2013 - 2017)
    • 9.3.2. By Value (2018 - 2023)

10. Global Growth Hormone Deficiency Drugs Market: Country Analysis

  • 10.1. U.S. Growth Hormone Deficiency Drugs Market
    • 10.1.1. By Value (2013 - 2017)
    • 10.1.2. By Value (2018 - 2023)
  • 10.2. U.K. Growth Hormone Deficiency Drugs Market
    • 10.2.1. By Value (2013 - 2017)
    • 10.2.2. By Value (2018 - 2023)
  • 10.3. France Growth Hormone Deficiency Drugs Market
    • 10.3.1. By Value (2013 - 2017)
    • 10.3.2. By Value (2018 - 2023)
  • 10.4. Germany Growth Hormone Deficiency Drugs Market
    • 10.4.1. By Value (2013 - 2017)
    • 10.4.2. By Value (2018 - 2023)
  • 10.5. Spain Growth Hormone Deficiency Drugs Market
    • 10.5.1. By Value (2013 - 2017)
    • 10.5.2. By Value (2018 - 2023)
  • 10.6. Japan Growth Hormone Deficiency Drugs Market
    • 10.6.1. By Value (2013 - 2017)
    • 10.6.2. By Value (2018 - 2023)

11. human Growth Hormone Deficiency (hGHD) Pipeline Drugs - An Analysis

  • 11.1. hGHD Pipeline Drugs - TransCon-hGH
    • 11.1.1. Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Advantages & Disadvantages
    • 11.1.4. Product Profile & Launch Date
    • 11.1.5. Clinical Trials and Status
    • 11.1.6. Pivotal Clinical Trials and Results
    • 11.1.7. TransCon-hGH - Global Market Potential
    • 11.1.8. TransCon-hGH - Global Market Potential
  • 11.2. hGHD Pipeline Drugs - Somapacitan
    • 11.2.1. Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Advantages & Disadvantages
    • 11.2.4. Product Profile & Launch Date
    • 11.2.5. Clinical Trials and Status
    • 11.2.6. Pivotal Clinical Trials and Results
    • 11.2.7. Somapacitan - Global Market Potential
    • 11.2.8. Somapacitan - 7Ps Analysis
  • 11.3. hGHD Pipeline Drugs - Somavaratan
    • 11.3.1. Description
    • 11.3.2. Regulatory Milestones
    • 11.3.3. Advantages & Disadvantages
    • 11.3.4. Product Profile & Launch Date
    • 11.3.5. Clinical Trials and Status
    • 11.3.6. Pivotal Clinical Trials and Results
    • 11.3.7. Somavaratan - Global Market Potential
    • 11.3.8. Somavaratan - 7Ps Analysis
  • 11.4. hGHD Pipeline Drugs - Somatrogon/ Lagova
    • 11.4.1. Description
    • 11.4.2. Regulatory Milestones
    • 11.4.3. Advantages & Disadvantages
    • 11.4.4. Product Profile & Launch Date
    • 11.4.5. Clinical Trials and Status
    • 11.4.6. Pivotal Clinical Trials and Results
    • 11.4.7. Somatrogon/ Lagova - Global Market Potential
    • 11.4.8. Somatrogon/ Lagova - 7Ps Analysis
  • 11.5. Competitive Landscape

12. Company Profiles

  • 12.1. Ascendis Pharma A/S
  • 12.2. Novo Nordisk A/S
  • 12.3. Versartis Inc.
  • 12.4. Opko Health, Inc.
  • 12.5. Pfizer Inc
Back to Top